Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ER niacin/laropiprant added to statin versus doubled statin dose in hypercholesterolemia or mixed dyslipidemia
2007-002017-39Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of laropiprant, simvastatin and atorvastatin in hypercholesterolemia and combined dyslipidaemia (2 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline in LDL-C at Week 12. Started May 2007; status: completed.
02
Drugs
laropiprantsimvastatinatorvastatin
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2007-002017-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002017-39.